Hyperhidrosis News and Research

RSS

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

Cutting cardiac sympathetic nerve may help control heart rhythms

What do sweaty palms and abnormal heart rhythms have in common? Both can be initiated by the nervous system during adrenaline-driven "flight or fight" stress reaction when the body senses danger.

20 Dec 2011

Sweat meter could alert diabetes patients about low blood sugar

Some diabetic patients receive no warning before they pass out from low blood sugar. A modern sweat meter could alert patients in time. Biathletes and ME patients might also benefit from the sweat meter.

31 Aug 2011

Scientist develops new ETS procedure to treat hyperhidrosis

Millions of people in the United States suffer from a medical condition that can unpredictably cause them to begin sweating as if they had just finished running a marathon.Hyperhidrosis, or excessive sweating, is a common disorder that first becomes noticeable during childhood or adolescence. People with hyperhidrosis could be doing something as leisurely as lying down or watching television and sweat will still soak their bodies.

2 Sep 2010

IMPACT trial shows improvement in OS for metastatic CRPC

Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," during the second plenary session of the 25th Anniversary EAU Congress in Barcelona.

21 Apr 2010

Allergan celebrates 20th anniversary of BOTOX in Canada

Twenty years ago, the first approved use of BOTOX(R) (botulinum toxin type A), a neurotoxin widely used to treat several life altering medical conditions, was granted in Canada. As part of the 20th anniversary celebrations, healthcare professionals from coast to coast reflect upon the discovery, science and evolution of a therapy that has impacted the lives of millions of patients worldwide.

3 Mar 2010

IHHS website provides medical resources for people suffering from dermatologic disorder

Therese has suffered with a dermatologic disorder called Hyperhidrosis since she was six years old, leaving her with perpetually wet hands and feet.

9 Feb 2010

Excessive sweating disorder can negatively influence job prospects

If success is one per cent inspiration and ninety-nine percent perspiration, then it might follow that the Hyperhidrosis sufferer should have no trouble gaining employment. Not so fast.

9 Jan 2010

Revance Therapeutics closes $35 million Series D financing

Revance Therapeutics, Inc. (“Revance”) today announced the first $25 million closing of a $35 million Series D financing. The round was led by Essex Woodlands Health Ventures Fund VIII.

4 Jan 2010

Cymbalta maintains reduction in pain for patients with chronic low back pain

New data show patients with chronic low back pain on Cymbalta(R) (duloxetine HCl) maintained reductions in pain for 41 weeks. In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in pain that was statistically significant as measured by the Brief Pain Inventory (BPI) average pain rating.

11 Sep 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

Changes in medical terminology confuses patients

The label used to identify a disease - whether it is common language or medical terminology - can influence how serious people think the condition is, according to new research from McMaster University, the second part of a larger study on how people understand and interpret disease.

8 Dec 2008

Cymbalta approved in Europe for generalised anxiety disorder

Eli Lilly and Co and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD).

24 Aug 2008

FDA approves PRISTIQ for the treatment of adult patients with major depressive disorder

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the U.S. Food and Drug Administration (FDA) has approved PRISTIQ (desvenlafaxine), a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD).

3 Mar 2008

Innovative treatment option for excessive sweating

An estimated 3 percent of the world population, or about 197 million people suffer from some form of hyperhidrosis (excessive sweating), many of whom do not receive proper diagnosis or treatment.

17 Apr 2007

FDA approves antidepressant Cymbalta (duloxetine HCl) for treatment of generalized anxiety disorder

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved the antidepressant Cymbalta (duloxetine HCl) for the treatment of generalized anxiety disorder (GAD), a condition that affects more than 6.5 million American adults in a given year.

26 Feb 2007

Botox - other applications

While botulinum toxin A, or BTXA, is widely known for its use in dermatology and aesthetic medicine, a review article in the Journal of Cosmetic Dermatology explores the drug’s other successful applications.

12 Dec 2005

Botox controls excess sweating as well as ironing out those wrinkles

According to researchers at the St. Louis University School of Medicine, Botox may do more than plump out those wrinkles.

25 Jul 2005

Broader range of treatments for excessive sweating disorder, Mayo Clinic Proceedings says

The often embarrassing, excessive sweating disorder, hyperhidrosis, and its treatment options are gaining greater attention from physicians. This is improving the efficacy of treatment and minimizing its adverse effects, Mayo Clinic authors write in the May issue of Mayo Clinic Proceedings.

11 May 2005

Excessive sweating now has less invasive treatment

For about one percent of Americans, excessive sweating isn’t just embarrassing; it’s a condition that warrants medical treatment. Now, a minimally invasive, endoscopic approach available at Georgetown University Hospital allows patients to receive this treatment and go home the same day.

25 Oct 2004